ClinicalTrials.gg
CompletedNCT05068440Updated Mar 25, 2026Results posted

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

A Phase 2 interventional study of Zanubrutinib in Relapsed Diffuse Large B-cell Lymphoma and Refractory Diffuse Large B-cell Lymphoma, sponsored by BeiGene. Completed at 25 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse — 19 open to participants now, 23 under way, 1 of them phase 3. zanubrutinib · Lymphoma, Large B-Cell, Diffuse.

Enrollment
7th of 30
65 · median 39
Started
2021
with 3 others
Phase 2
26 of 30
17 open now
Registered
8th of 30
by date
Lead sponsor
4 of 30
BeiGene

Among the 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 7th largest by enrollment, is one of 4 that started in 2021, is one of 26 in phase 2, and was the 8th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

19 of the 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 2 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

About zanubrutinib

zanubrutinib: first FDA approval 2019 (BRUKINSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

The goal of this clinical trial was to evaluate whether zanubrutinib can effectively treat adults with CD79B-mutant relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Participants received zanubrutinib as monotherapy, underwent regular disease assessments to evaluate treatment response, and were monitored for safety and side effects throughout the study.

03

Conditions studied

  • Relapsed Diffuse Large B-cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants had confirmed diffuse large B-cell lymphoma, based on the World Health Organization 2008 classification of tumors of hematopoietic and lymphoid tissue.
  2. Participants had a positive CD79B gene mutation, as confirmed by a central laboratory.
  3. Participants had previously received at least one line of adequate systemic therapy for diffuse large B-cell lymphoma, defined as anti-CD20 antibody-based chemoimmunotherapy administered for at least two consecutive cycles, unless disease progression occurred before completion of Cycle 2.
  4. Participants had disease prior to study entry, defined as either:

    1. Recurrent disease after achieving disease remission, defined as a complete response or partial response, at the completion of the most recent treatment regimen; or
    2. Stable disease or progressive disease at the completion of the most recent treatment regimen.
  5. Participants were ineligible for high-dose therapy and stem cell transplantation, defined as meeting at least one of the following criteria:

    a. Presence of significant organ dysfunction, such as:

    1. less than 50 percent as measured by echocardiogram or multiple gated acquisition scan;
    2. Diffusing capacity of the lung for carbon monoxide less than 60 percent of the predicted value as measured by pulmonary function testing; or
    3. less than 70 milliliters per minute as demonstrated by nuclear medicine scan or 24-hour urine collection; or comorbid conditions that precluded the use of high-dose therapy and stem cell transplantation due to an unacceptable risk of treatment-related morbidity.

    b. Failure to achieve a complete response or partial response following salvage therapy.

    c. Failure to collect stem cells or inability to undergo stem cell collection, as assessed by the investigator.

Exclusion criteria

Exclusion Criteria

  1. Participants had non-Hodgkin lymphoma other than classical histology diffuse large B-cell lymphoma (not otherwise specified), including but not limited to:

    1. Diffuse large B-cell lymphoma transformed from indolent lymphomas
    2. Primary mediastinal (thymic) large B-cell lymphoma
    3. Primary cutaneous diffuse large B-cell lymphoma
    4. Primary effusion lymphoma
    5. Central nervous system lymphoma
  2. Participants had a history of stem cell transplantation or chimeric antigen receptor T-cell therapy.
  3. Participants had prior exposure to a Bruton's tyrosine kinase inhibitor.
  4. Participants had received any of the following treatments within the specified timeframe prior to the first dose of study drug:

    1. administered with antineoplastic intent within two weeks prior to study treatment. A short course (seven days or fewer) of systemic corticosteroids at doses of 20 milligrams per day or less of prednisone equivalent for control of lymphoma-related symptoms was permitted prior to enrollment, provided the corticosteroids were tapered off within five days after initiation of study treatment.
    2. Chemotherapy or radiotherapy within two weeks.
    3. Monoclonal antibody therapy within two weeks.
    4. therapy within two weeks.
    5. Chinese patent medicine administered with antineoplastic intent within two weeks.
  5. Participants had a history of other active within two years prior to study entry, with the exception of:

    1. Adequately treated carcinoma in situ of the cervix;
    2. Localized basal cell carcinoma or squamous cell carcinoma of the skin; or
    3. A previous malignancy that was confined and treated locally (by surgery or other modality) with curative intent.

Note: Other protocol-defined inclusion and exclusion criteria may have applied.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Zanubrutinib

    Participants received zanubrutinib 160 mg orally twice daily, administered continuously until disease progression, unacceptable toxicity, withdrawal of consent, initiation of alternative anticancer therapy, loss to follow-up, or study completion.

    Drug: Zanubrutinib

Interventions

  • Administered orally as capsules at a dose of 160 mg twice daily on a continuous dosing schedule.

    Also known as: BGB-3111, Brukinsa

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Defined as the percentage of participants who achieved complete response (CR) or partial response (PR) by investigator assessment according to the Lugano classification for Non-Hodgkin's Lymphoma (NHL).

    Time frame: Response was assessed every 12 weeks for the first 24 months and every 24 weeks thereafter. Maximum time on study was 36.4 months

Secondary outcomes

  1. Complete Response Rate (CRR)

    CRR was defined as the percentage of participants who achieved a complete response as their best overall response, as determined by investigator assessment according to the Lugano classification for NHL.

    Time frame: Response was assessed every 12 weeks for the first 24 months and every 24 weeks thereafter. Maximum time on study was 36.4 months

  2. Duration of Response (DOR)

    DOR was defined as the time from the date that a confirmed response (CR or PR) was first observed to the date of first documented disease progression or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method.

    Time frame: From the date of first documented response until to the data cutoff date (31MAR2025). Maximum time on study was 36.4 months

  3. Progression-free Survival (PFS)

    PFS is defined as time from start of treatment to the first documentation of disease progression or death, whichever occurs first as determined by investigator assessment according to the Lugano classification for NHL. Median PFS was estimated using the Kaplan-Meier method.

    Time frame: From first dose until the data cutoff date (31MAR2025). Maximum time on study was 36.4 months

  4. Time to Response (TTR)

    TRR was defined as the time from randomization to the first date that response criteria (CR or PR) were met, as determined by investigator assessment per the Lugano classification for NHL. Only participants who achieved an overall response were included in the analysis.

    Time frame: From first dose until disease progression or death, assessed up to the data cutoff date (31MAR2025). Maximum time on study was 36.4 months

  5. Overall Survival (OS)

    OS was defined as the time from randomization to the date of death from any cause. Median OS was estimated using the Kaplan-Meier method.

    Time frame: From first dose until the data cutoff date (31MAR2025). Maximum time on study was 36.4 months

  6. Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An adverse event refers to any unintended or unfavorable sign, symptom, or condition (including abnormal lab results) that occurs during the study, regardless of whether it was linked to the study drug.

    Time frame: From the first dose until 30 days after the last dose of zanubrutinib, death, or initiation of new anticancer therapy, whichever occurred first, assessed up to the data cutoff date (31MAR2025). Maximum treatment duration was 36.4 months

07

Results

Posted Mar 25, 2026

Participant flow

Participants were enrolled at 20 study centers in China.

Participant flow — Overall Study
MilestoneZanubrutinib
Started65
Treated65
Completed16
Not completed49
Withdrew: Death32
Withdrew: Lost to follow-up2
Withdrew: Withdrawal by subject1
Withdrew: Study completed by sponsor14

Outcome measures

PrimaryOverall Response Rate (ORR)

Defined as the percentage of participants who achieved complete response (CR) or partial response (PR) by investigator assessment according to the Lugano classification for Non-Hodgkin's Lymphoma (NHL).

Time frame:
Response was assessed every 12 weeks for the first 24 months and every 24 weeks thereafter. Maximum time on study was 36.4 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsZanubrutinib
Overall Response Rate (ORR)46.2 (33.7 to 59.0)
Statistical analysis
  • Zanubrutinib · Binomial Exact Test · p = 0.0044One-sided p-value calculated using the binomial exact test versus a historical ORR of 30%. Threshold for statistical significance was 0.025.
SecondaryComplete Response Rate (CRR)

CRR was defined as the percentage of participants who achieved a complete response as their best overall response, as determined by investigator assessment according to the Lugano classification for NHL.

Time frame:
Response was assessed every 12 weeks for the first 24 months and every 24 weeks thereafter. Maximum time on study was 36.4 months
Reported as:
Number · Percentage of Participants
Complete Response Rate (CRR)
Percentage of ParticipantsZanubrutinib
Complete Response Rate (CRR)29.2 (18.6 to 41.8)
SecondaryDuration of Response (DOR)

DOR was defined as the time from the date that a confirmed response (CR or PR) was first observed to the date of first documented disease progression or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method.

Time frame:
From the date of first documented response until to the data cutoff date (31MAR2025). Maximum time on study was 36.4 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsZanubrutinib
Duration of Response (DOR)22.7 (2.8 to NA)
SecondaryProgression-free Survival (PFS)

PFS is defined as time from start of treatment to the first documentation of disease progression or death, whichever occurs first as determined by investigator assessment according to the Lugano classification for NHL. Median PFS was estimated using the Kaplan-Meier method.

Time frame:
From first dose until the data cutoff date (31MAR2025). Maximum time on study was 36.4 months
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsZanubrutinib
Progression-free Survival (PFS)4.3 (2.7 to 5.5)
SecondaryTime to Response (TTR)

TRR was defined as the time from randomization to the first date that response criteria (CR or PR) were met, as determined by investigator assessment per the Lugano classification for NHL. Only participants who achieved an overall response were included in the analysis.

Time frame:
From first dose until disease progression or death, assessed up to the data cutoff date (31MAR2025). Maximum time on study was 36.4 months
Reported as:
Median · Months
Time to Response (TTR)
MonthsZanubrutinib
Time to Response (TTR)2.76 (0.9 to 5.5)
SecondaryOverall Survival (OS)

OS was defined as the time from randomization to the date of death from any cause. Median OS was estimated using the Kaplan-Meier method.

Time frame:
From first dose until the data cutoff date (31MAR2025). Maximum time on study was 36.4 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsZanubrutinib
Overall Survival (OS)18.1 (11.4 to NA)
SecondaryNumber of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An adverse event refers to any unintended or unfavorable sign, symptom, or condition (including abnormal lab results) that occurs during the study, regardless of whether it was linked to the study drug.

Time frame:
From the first dose until 30 days after the last dose of zanubrutinib, death, or initiation of new anticancer therapy, whichever occurred first, assessed up to the data cutoff date (31MAR2025). Maximum treatment duration was 36.4 months
Reported as:
Count of participants · Participants
Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsZanubrutinib
At Least One TEAE59
At Least One SAE16

Adverse events

Collected over From the first dose until 30 days after the last dose of zanubrutinib or initiation of new anticancer therapy, whichever occurred first, assessed up to the data cutoff date (31MAR2025). Maximum treatment duration was 36.4 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zanubrutinib32/65 (49.2%)16/65 (24.6%)57/65 (87.7%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventZanubrutinib
PneumoniaInfections and infestations4/65
Acute coronary syndromeCardiac disorders1/65
Abdominal adhesionsGastrointestinal disorders1/65
AscitesGastrointestinal disorders1/65
Gastrointestinal perforationGastrointestinal disorders1/65
Ileal perforationGastrointestinal disorders1/65
IleusGastrointestinal disorders1/65
Upper gastrointestinal haemorrhageGastrointestinal disorders1/65
Chest discomfortGeneral disorders1/65
Sudden cardiac deathGeneral disorders1/65
Most frequent other events
Showing 10 of 60
Most frequent other events
EventZanubrutinib
AnaemiaBlood and lymphatic system disorders22/65
Neutrophil count decreasedInvestigations22/65
Platelet count decreasedInvestigations20/65
White blood cell count decreasedInvestigations19/65
Aspartate aminotransferase increasedInvestigations13/65
Blood lactate dehydrogenase increasedInvestigations12/65
HypoalbuminaemiaMetabolism and nutrition disorders12/65
PyrexiaGeneral disorders11/65
Alanine aminotransferase increasedInvestigations11/65
PneumoniaInfections and infestations9/65

Baseline characteristics

The Safety Analysis Set included all participants who received at least 1 dose of zanubrutinib.

Age, Continuous
Age, Continuous(years)Zanubrutinib
Mean65.3 ± 9.88
Sex: Female, Male
Sex: Female, Male(Participants)Zanubrutinib
Female31
Male34
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zanubrutinib
Asian65
The Eastern Cooperative Oncology Group (ECOG) Performance Status
The Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Zanubrutinib
0 (fully Active)12
1 (Limited strenuous activity; light work possible)43
2 (Self-care intact; no work; up >50% of day)10
08

Study locations

25 sites
  • Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital
    Hefei, Anhui 230088, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing Municipality 100050, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
  • Sun Yat Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Guangdong Provincial Peoples Hospital Huifu Branch
    Guangzhou, Guangdong 510120, China
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510120, China
  • The First Affiliated Hospital of Shantou University Medical College
    Shantou, Guangdong 515041, China
  • Hainan Cancer Hospital
    Haikou, Hainan 570312, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • The First Affiliated Hospital of Nanchang University Branch Donghu
    Nanchang, Jiangxi 330006, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Liaoning Cancer Hospital and Institute
    Shenyang, Liaoning 110042, China
  • Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200025, China
  • Shanxi Provincial Cancer Hospital
    Taiyuan, Shanxi 030013, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Institute of Hematology and Hospital of Blood Disease
    Tianjin, Tianjin Municipality 300020, China
  • Yunnan Cancer Hospital
    Kunming, Yunnan 650100, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
  • Zhejiang University College of Medicine Second Affiliated Hospital
    Hangzhou, Zhejiang 310009, China
  • Taizhou Hospital of Zhejiang
    Taizhou, Zhejiang 317000, China
09

References and documents

Publications

  • Li Wang, Fei Li, Qingyuan Zhang, Hui Zhou, Ou Bai, Liping Su, Chunhong Hu, Zhiming Li, Kaiyang Ding, Qunyi Guo, Xiaoling Li, Xiaoxi Zhou, Wenjuan Yu, Shuhua Yi, Zhixia Wei, Wenbin Qian, Feiheng Chen, Guohui Cui, Zhiyu Liang, Qingchao Zeng, Jiaoyan Lyu, Yang Liu, Pan Zhang, Zhirong Shen, Zaixing Shi, Jing Rong, Keshu Zhou, Weili Zhao; BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Blood 2025; 146 (Supplement 1): 3684. doi: https://doi.org/10.1182/blood-2025-3684

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Mar 2025, 43 months.

Results were first posted in Mar 2026, 11 months after primary completion.

Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 43 months is above that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2021
First posted
Oct 5, 2021
StartActual
Aug 11, 2021
Primary completionActual
Mar 31, 2025
CompletionActual
Mar 31, 2025
Results first posted
Mar 25, 2026
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05068440
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Oct 5, 2021
Start date
Aug 11, 2021
Primary completion
Mar 31, 2025
Completion
Mar 31, 2025
Results posted
Mar 25, 2026
Last update
Mar 25, 2026

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion